Review, Editorial, and Original Research Articles on EID
Last Reviewed March 2025
Disclaimer: This content is provided for educational purposes only and is not a substitute for independent clinical judgment. Always consult official product monographs and prescribing information before making treatment decisions. Do not delay or disregard professional medical advice because of information on this site. Use of this resource does not establish a physician–patient relationship. See the full disclaimer for details.
A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab
Journal of Immunotherapy. 2021; 00: 000-000
A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors
International Immunopharmacology. 2022; 108: 108775. doi: 10.1016/j.intimp.2022.108775
A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan
Frontiers in Medicine. 2023; 10: 1293397. doi: 10.3389/fmed.2023.1293397
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modeling and simulation
European Journal of Cancer. 2020; 131; 68-75
Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation
JAMA Oncol. 2022; 8(11): 1663-1667
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
Current Oncology. 2022; 29(11): 8686-8692
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens with Survival Outcomes in Advanced Non-small cell Lung Cancer
Clinical Lung Cancer. 2021; 22(3): e379-389
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study
ESMO Open 2023; 8(6):102070. doi: 10.1016/j.esmoop.2023.102070
Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question
Clinical and translational oncology. 2021; 23(8): 1511-1519
Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study
Journal of Clinical Oncology. 2022 ASCO Annual Meeting. Abstract 2595
Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
Frontiers of Oncology. 2020; 10(1193): 1-9
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients
2024; 130(11): 1866-1874
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
Journal for Immunotherapy of Cancer. 2024; 12(3): e008325.doi: 10.1136/jitc-2023-008325
Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen
2021; 10(4): 1917-1923
Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic
2023; 83:101004. doi: 10.1016/j.resmer.2023.101004
KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma
Journal of Clinical Oncology. 2021 ASCO Annual Meeting. Abstract 9541
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
Annals of Oncology. 2019; 30(4): 644-651
Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors
JAMA Network Open. 2023; 6(2): e230490. doi:10.1001/jamanetworkopen.2023.0490
Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic
2022; 23(2): 143-150
Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC
Journal of Thoracic Oncology. 2023; 18(2): e14-e16
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
Journal of National Cancer Institute. 2023; 00(0): 1-9
Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer
AME Clinical Trials Review. 2024; 2: 17
When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents
Targeted Oncology. 2022; 17(3): 253-270
